Details of the Drug
General Information of Drug (ID: DML5AE4)
Drug Name |
FK-3311
|
||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
116686-15-8; FK 3311; FK-3311; FK3311; COX-2 Inhibitor V, FK3311; N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]methanesulfonamide; N-(4-Acetyl-2-(2,4-difluorophenoxy)phenyl)methanesulfonamide; 4'-Acetyl-2'-(2,4-difluorophenoxy)methanesulfonanilide; Methanesulfonamide, N-[4-acetyl-2-(2,4-difluorophenoxy)phenyl]-; C15H13F2NO4S; Methanesulfonamide, N-(4-acetyl-2-(2,4-difluorophenoxy)phenyl)-; DIIYLGZNZGPXRR-UHFFFAOYSA-N; AC1L4U0O; AC1Q6W4K; SCHEMBL441676; ZINC3880; DIIYLGZNZGPXRR-UHFFFAOYSA-; CTK8E9207; EX-A545; DTXSID90151474
|
||||||||||||||||||||||
Indication |
|
||||||||||||||||||||||
Drug Type |
Small molecular drug
|
||||||||||||||||||||||
Structure | |||||||||||||||||||||||
3D MOL | 2D MOL | ||||||||||||||||||||||
#Ro5 Violations (Lipinski): 0 | Molecular Weight (mw) | 341.3 | |||||||||||||||||||||
Logarithm of the Partition Coefficient (xlogp) | 2.3 | ||||||||||||||||||||||
Rotatable Bond Count (rotbonds) | 5 | ||||||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 1 | ||||||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 7 | ||||||||||||||||||||||
Chemical Identifiers |
|
||||||||||||||||||||||
Cross-matching ID | |||||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | |||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Rheumatoid arthritis | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | FA20 | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||